RecruitingNCT05152238
ITP Registry and Accompanying Biospecimen Collection
Studying Autoimmune thrombocytopenia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Jena University Hospital
- Principal Investigator
- Thomas Stauch, Dr. med.Jena University Hospital
- Enrollment
- 1100 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2027
Study locations (30)
- Universitätsklinikum Aachen AöR, Aachen, Germany
- Klinikum Altenburger Land GmbH, Klinik für Innere Medizin/Hämatologie/Onkologie, Altenburg, Germany
- MVZ am Klinikum Aschaffenburg, Aschaffenburg, Germany
- MVZ IMD GmbH, IMD Gerinnungszentrum Hochtaunus, Bad Homburg, Germany
- Onkologie/Hämatologie, Bad Liebenwerda, Germany
- Charité Universitätsmedizin Berlin, Berlin, Germany
- Praxis für Hämatologie und Onkologie Berlin-Mitte, Berlin, Germany
- Vivantes Netzwerk für Gesundheit GmbH, Klinikum am Friedrichshain, Berlin, Germany
- Onkologie am Segelfliegerdamm, Berlin, Germany
- MVZ Hämatologikum GmbH, Biberach, Germany
- Augusta-Kranken-Anstalt gGmbH, Bochum, Germany
- Klinikum Chemnitz gGmbH, Chemnitz, Germany
- MVZ Klinikum Coburg GmbH, Coburg, Germany
- Klinikum Darmstadt, Darmstadt, Germany
- ARGE e.V., Donauwörth, Germany
- +15 more locations on ClinicalTrials.gov
Collaborators
University Hospital Dresden · Novartis · Swedish Orphan Biovitrum · Grifols Biologicals, LLC · Amgen · argenx
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05152238 on ClinicalTrials.govOther trials for Autoimmune thrombocytopenia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07559331High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune ThrombocytopeniaShandong University
- RECRUITINGPHASE2NCT07362238Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07362199Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGEARLY PHASE1NCT07441525UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological DiseasesUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGPHASE2NCT07234019Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07297563Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07294365A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)Dizal Pharmaceuticals
- RECRUITINGPHASE2NCT07104565Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell DisordersIncyte Corporation